CCL17 and neoplasm: It is reported that eosinophils may promote tumour rejection through secretion of CD8+ and CD4+ T cell chemo-attractants, such as CXCL9, CXCL10, CCL5 (via STAT1) or CCL17, CCL22 (via STAT6), which allow the trafficking of T cells to the tumour site18.